Literature DB >> 20808116

Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study.

James E Emanuel1, Oscar L Lopez, Patricia R Houck, James T Becker, Elise A Weamer, Mary Ann A Demichele-Sweet, Lewis Kuller, Robert A Sweet.   

Abstract

OBJECTIVE: To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI).
DESIGN: : The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data.
SETTING: Community. PARTICIPANTS: The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-∊ (APOE) genotyping. MEASUREMENTS: The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status.
RESULTS: : Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis.
CONCLUSIONS: Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process.

Entities:  

Mesh:

Year:  2011        PMID: 20808116      PMCID: PMC3000865          DOI: 10.1097/JGP.0b013e3181e446c8

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  28 in total

1.  Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features.

Authors:  R A Sweet; R L Hamilton; O L Lopez; W E Klunk; S R Wisniewski; D I Kaufer; M T Healy; S T DeKosky
Journal:  Int Psychogeriatr       Date:  2000-12       Impact factor: 3.878

Review 2.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

3.  Increased familial risk of the psychotic phenotype of Alzheimer disease.

Authors:  R A Sweet; V L Nimgaonkar; B Devlin; O L Lopez; S T DeKosky
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

4.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

5.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

6.  Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology.

Authors:  Robert A Sweet; Kanagasabai Panchalingam; Jay W Pettegrew; Richard J McClure; Ronald L Hamilton; Oscar L Lopez; Daniel I Kaufer; Steven T DeKosky; William E Klunk
Journal:  Neurobiol Aging       Date:  2002 Jul-Aug       Impact factor: 4.673

7.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.

Authors:  M F Elias; A Beiser; P A Wolf; R Au; R F White; R B D'Agostino
Journal:  Arch Neurol       Date:  2000-06

Review 8.  Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype.

Authors:  R A Sweet; V L Nimgaonkar; B Devlin; D V Jeste
Journal:  Mol Psychiatry       Date:  2003-04       Impact factor: 15.992

9.  Evaluation of dementia in the cardiovascular health cognition study.

Authors:  Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp
Journal:  Neuroepidemiology       Date:  2003 Jan-Feb       Impact factor: 3.282

Review 10.  Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies.

Authors:  David A Lewis; Robert A Sweet
Journal:  J Clin Invest       Date:  2009-04-01       Impact factor: 14.808

View more
  33 in total

1.  Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet
Journal:  J Clin Psychiatry       Date:  2016-12       Impact factor: 4.384

2.  Gray Matter Changes Associated With the Development of Delusions in Alzheimer Disease.

Authors:  Winnie Qian; Tom A Schweizer; Nathan W Churchill; Colleen Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; David G Munoz; Joseph J Barfett; Tarek K Rajji; Corinne E Fischer
Journal:  Am J Geriatr Psychiatry       Date:  2018-10-02       Impact factor: 4.105

3.  TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.

Authors:  Su Hee Chu; Kathryn Roeder; Robert E Ferrell; Bernie Devlin; Mary Ann A DeMichele-Sweet; M Ilyas Kamboh; Oscar L Lopez; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2011-08-05       Impact factor: 4.673

4.  β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis.

Authors:  Patrick S Murray; Caitlin M Kirkwood; Megan C Gray; Milos D Ikonomovic; William R Paljug; Eric E Abrahamson; Ruth A Henteleff; Ronald L Hamilton; Julia K Kofler; William E Klunk; Oscar L Lopez; Peter Penzes; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2012-03-17       Impact factor: 4.673

Review 5.  Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders.

Authors:  Peter Penzes; Andres Buonanno; Maria Passafaro; Carlo Sala; Robert A Sweet
Journal:  J Neurochem       Date:  2013-05-22       Impact factor: 5.372

6.  Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease.

Authors:  Winnie Qian; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

Review 7.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

8.  Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients.

Authors:  Lirong Wang; Jian Ying; Peihao Fan; Elise A Weamer; Mary Ann A DeMichele-Sweet; Oscar L Lopez; Julia K Kofler; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-27       Impact factor: 4.105

9.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

10.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.